KZA 3.53% 44.0¢ kazia therapeutics limited

497-509

  1. 25,374 Posts.
    lightbulb Created with Sketch. 2
    sorry if this is a rpt
    my lookup function is timing out...
    new generation pharmaceuticals
    ASX & MEDIA RELEASE
    18 AUGUST 2003
    NOVOGEN AWARDED US PATENT FOR ISOFLAVONES TO TREAT ESTROGEN DEPENDENT
    DISEASE
    Pharmaceutical company, Novogen Limited, has been granted a patent in the US over the use of its
    isoflavone technology for the treatment of estrogen-dependent disorders such as fibroids and
    endometriosis in women.
    This gives Novogen the option to produce patented dietary supplements for younger women to
    alleviate estrogen-dependent disorders such as fibroids and endometriosis.
    Fibroids symptoms affect 25% of women, usually in younger age groups and occurs as a result of
    excessive stimulation of the reproductive organs by endogenous estrogen. This causes benign
    outgrowth of ovarian tissue which can result in abdominal swelling and pain. Current treatments
    usually involve surgical removal.
    Endometriosis affects up to 10% of women again usually in younger age groups, and is a condition
    where tissue forming the uterine lining begins to grow outside the uterus in the abdominal cavity.
    This is a life threatening condition and because of the diffuse nature of these growths is very difficult
    to treat and causes long term chronic pain and distress.
    Both conditions are fuelled by over production of estrogen and ultimately may only be treated
    effectively by combined hysterectomy and ovariectomy.
    The key finding covered by Novogen’s patent is that natural plant estrogens, known as isoflavones,
    can antagonise the ability of a woman’s own estrogen to fuel the growth of these tissues.
    Novogen’s research director, Professor Alan Husband said it was an apparent paradox that natural
    estrogens may top up estrogen effects in older women but dampen their effects in younger women
    where their own estrogen was abundant.
    “Part of Novogen’s discovery is that the isoflavones found in red clover compete weakly for estrogen
    receptors and in the absence of endogenous hormone estrogen, as occurs in women after
    menopause, can stimulate these receptors to provide a surrogate estrogen effect,” Professor Husband
    said.
    “In younger women, when most of the receptors are being stimulated by their own estrogen, the
    weakly acting plant estrogens compete for the binding sites and when they stimulate the receptors
    produce only a we ak estrogenic signal, thus dampening the overall estrogenic stimulus at these
    sites.”
    The patent applies to the isoflavones genistein, daidzein, formononetin and biochanin, all of which
    are contained in red clover isoflavone supplements currently marketed by the Company for
    management of menopause symptoms and long term effects of estrogen deficiency.
    2
    Novogen’s Managing Director, Mr Christopher Naughton, said adding another patent to the suite
    protecting the Company’s isoflavone technology would consolidate Novogen’s market leadership in
    this sector.
    “We will be able to create new commercial opportunities by extending our supplement product range
    to cater for younger women,” Mr Naughton said.
    “Novogen will also maintain its leadership role in this important area of non-prescription treatments
    for women’s health problems through its ongoing development of novel science coupled with
    advanced manufacturing processes to provide natural and safe alternatives to prescription estrogen
    products.”
    Novogen’s isoflavone products are marketed globally and the Company coordinates and manages its
    research and development programs utilising the expertise and clinical research capabilities of
    universities and hospitals in Australia and key international locations.
    More information on the Company can be found at www.novogen.com.
    ISSUED FOR : NOVOGEN LIMITED
    LISTINGS : ASX (CODE NRT), NASDAQ (CODE NVGN).
    FOR FURTHER
    INFORMATION : PROFESSOR ALAN HUSBAND, RESEARCH DIRECTOR
    NOVOGEN LIMITED, TEL (02) 9878 0088
    ISSUED BY : WESTBROOK COMMUNICATIONS
    CONTACT: DAVID REID TEL (02) 9231 0922 OR 0417 217 157


    appears to be back filling todays gap up...?from open


 
watchlist Created with Sketch. Add KZA (ASX) to my watchlist
(20min delay)
Last
44.0¢
Change
0.015(3.53%)
Mkt cap ! $31.75M
Open High Low Value Volume
45.0¢ 45.0¢ 42.5¢ $30.07K 69.08K

Buyers (Bids)

No. Vol. Price($)
1 20000 43.0¢
 

Sellers (Offers)

Price($) Vol. No.
44.0¢ 10730 2
View Market Depth
Last trade - 15.12pm 20/11/2019 (20 minute delay) ?
(live)
Last
42.5¢
  Change
0.015 ( 0.00 %)
Open High Low Volume
44.5¢ 44.5¢ 42.5¢ 5711
Last updated 11.37am 20/11/2019 (live) ?
KZA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.